DRUG

Empagliflozin

14 hypotheses across 5 therapeutic domains

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

Empagliflozin appears in hypotheses across 5 disease domains: ALS, Epilepsy, Glioblastoma, Inflammatory bowel disease, Pancreatic cancer. Shared mediators that recur across at least two of those domains: AMPK.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for Empagliflozin

ALS 2

Mediator Outcome Score Tier Lit. status Trial
AMPK amyotrophic lateral sclerosis 0.277 High novel signal none
AMPK Alzheimer's disease 0.277 High reproduces known completed

Epilepsy 2

Mediator Outcome Score Tier Lit. status Trial
AMPK epileptiform network activity 0.277 High novel signal none
AMPK spike-wave seizures 0.277 High novel signal none

Glioblastoma 1

Mediator Outcome Score Tier Lit. status Trial
mTOR glioblastoma 0.208 Mid partial evidence none

Inflammatory bowel disease 3

Mediator Outcome Score Tier Lit. status Trial
AMPK intestinal epithelial repair 0.277 High novel signal none
AMPK intestinal inflammation 0.277 High partial evidence none
IL-17 Crohn's disease 0.208 Mid novel signal completed

Pancreatic cancer 6

Mediator Outcome Score Tier Lit. status Trial
SGLT2 pancreatic adenocarcinoma 0.326 High novel signal none
SGLT2 prostate adenocarcinoma 0.326 High novel signal none
AMPK pancreatic cancer progression 0.277 High novel signal none
AMPK invasion 0.277 High partial evidence none
AMPK pancreatic ductal adenocarcinoma 0.277 High novel signal none
PKM2 poor overall survival 0.248 Mid novel signal none

Clinical trials

200 registered trials for Empagliflozin

Source: ClinicalTrials.gov

← All drugs